Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 327341, 8 pages
http://dx.doi.org/10.1100/2012/327341
Review Article

Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?

Oncology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain

Received 25 October 2011; Accepted 17 November 2011

Academic Editors: C. Bosetti and L. Roncucci

Copyright © 2012 A. Manzano and P. Pérez-Segura. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. T. Lynch and A. de la Chapelle, “Hereditary colorectal cancer,” The New England Journal of Medicine, vol. 348, no. 10, pp. 919–932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. E. T. Hawk and B. Levin, “Colorrectal cancer prevention,” Journal of Clinical Oncology, vol. 23, pp. 378–391, 2005. View at Google Scholar
  4. T. A. Chan, “Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention,” The Lancet Oncology, vol. 3, no. 3, pp. 166–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Arber, “Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 8, pp. 1852–1857, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Pisani, F. Bray, and D. M. Parkin, “Estimates of the world-wide prevalence of cancer for 25 sites in the adult population,” International Journal of Cancer, vol. 97, no. 1, pp. 72–81, 2002. View at Publisher · View at Google Scholar
  7. G. A. Kune, S. Kune, and L. F. Watson, “Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study,” Cancer Research, vol. 48, no. 15, pp. 4399–4404, 1988. View at Google Scholar · View at Scopus
  8. “Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group,” The New England Journal of Medicine, vol. 312, no. 3, pp. 129–135, 1989.
  9. P. H. Gann, J. E. Manson, R. J. Glynn, J. E. Buring, and C. H. Hennekens, “Low-dose aspirin and incidence of colorectal tumors in a randomized trial,” Journal of the National Cancer Institute, vol. 85, no. 15, pp. 1220–1224, 1993. View at Google Scholar · View at Scopus
  10. T. Stürmer, R. J. Glynn, I. M. Lee, J. A. E. Manson, J. E. Buring, and C. H. Hennekens, “Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study,” Annals of Internal Medicine, vol. 128, no. 9, pp. 713–720, 1998. View at Google Scholar · View at Scopus
  11. N. R. Cook, I. M. Lee, J. M. Gaziano et al., “Low-dose aspirin in the primary prevention of cancer. The women's health study: a randomized controlled trial,” JAMA, vol. 294, no. 1, pp. 47–55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. Baron, B. F. Cole, R. S. Sandler et al., “A randomized trial of aspirin to prevent colorectal adenomas,” The New England Journal of Medicine, vol. 348, no. 10, pp. 891–899, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Benamouzig, J. Deyra, A. Martin et al., “Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial,” Gastroenterology, vol. 125, no. 2, pp. 328–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. S. Sandler, S. Halabi, J. A. Baron et al., “A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer,” The New England Journal of Medicine, vol. 348, no. 10, pp. 883–890, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. R. F. A. Logan, M. J. Grainge, V. C. Shepherd, N. C. Armitage, and K. R. Muir, “Aspirin and folic acid for the prevention of recurrent colorectal adenomas,” Gastroenterology, vol. 134, no. 1, pp. 29–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. F. Cole, R. F. Logan, S. Halabi et al., “Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials,” Journal of the National Cancer Institute, vol. 101, no. 4, pp. 256–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Dubé, A. Rostom, G. Lewin et al., “The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 146, no. 5, pp. 365–375, 2007. View at Google Scholar · View at Scopus
  18. E. Flossmann and P. M. Rothwell, “Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies,” The Lancet, vol. 369, no. 9573, pp. 1603–1613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. P. M. Rothwell, M. Wilson, C. E. Elwin et al., “Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials,” The Lancet, vol. 376, no. 9754, pp. 1741–1750, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Baron, R. S. Sandler, R. S. Bresalier et al., “A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas,” Gastroenterology, vol. 131, no. 6, pp. 1674–1682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. M. Bertagnolli, C. J. Eagle, A. G. Zauber et al., “Celecoxib for the prevention of sporadic colorectal adenomas,” The New England Journal of Medicine, vol. 355, no. 9, pp. 873–884, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. M. Bertagnolli, C. J. Eagle, A. G. Zauber et al., “Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial,” Cancer Prevention Research, vol. 2, no. 4, pp. 310–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Arber, C. J. Eagle, J. Spicak et al., “Celecoxib for the prevention of colorectal adenomatous polyps,” The New England Journal of Medicine, vol. 355, no. 9, pp. 885–895, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. R. S. Bresalier, R. S. Sandler, H. Quan et al., “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” The New England Journal of Medicine, vol. 352, no. 11, pp. 1092–1102, 2005. View at Publisher · View at Google Scholar
  25. S. D. Solomon, J. J. V. McMurray, M. A. Pfeffer et al., “Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention,” The New England Journal of Medicine, vol. 352, no. 11, pp. 1071–1080, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Rostom, C. Dubé, G. Lewin et al., “Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 146, no. 5, pp. 376–389, 2007. View at Google Scholar · View at Scopus
  27. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono, “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials,” British Medical Journal, vol. 332, no. 7553, pp. 1302–1305, 2006. View at Google Scholar · View at Scopus
  28. F. L. Meyskens, C. E. McLaren, D. Pelot et al., “Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial,” Cancer Prevention Research, vol. 1, no. 1, pp. 32–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Zell, D. Pelot, W. P. Chen, C. E. McLaren, E. W. Gerner, and F. L. Meyskens, “Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas,” Cancer Prevention Research, vol. 2, no. 3, pp. 209–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. W. Kinzler, M. C. Nilbert, L. K. Su et al., “Identification of FAP locus genes from chromosome 5q21,” Science, vol. 253, no. 5020, pp. 661–665, 1991. View at Google Scholar · View at Scopus
  31. H. R. J. Bussey, Familial Polyposis Coli: Family Studies, Histophatology, Diferential Diagnosis, and Results of Treatment, Johns Hopkins University Press, Baltimore, Md, USA, 1975.
  32. W. R. Waddell and R. W. Loughry, “Sulindac for polyposis of the colon,” Journal of Surgical Oncology, vol. 24, no. 1, pp. 83–87, 1983. View at Google Scholar · View at Scopus
  33. W. R. Waddell, G. F. Ganser, E. J. Cerise, and R. W. Loughry, “Sulindac for polyposis of the colon,” American Journal of Surgery, vol. 157, no. 1, pp. 175–179, 1989. View at Google Scholar · View at Scopus
  34. D. Labayle, D. Fischer, P. Vielh et al., “Sulindac causes regression of rectal polyps in familial adenomatous polyposis,” Gastroenterology, vol. 101, no. 3, pp. 635–639, 1991. View at Google Scholar · View at Scopus
  35. F. M. Giardiello, S. R. Hamilton, A. J. Krush et al., “Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis,” The New England Journal of Medicine, vol. 328, no. 18, pp. 1313–1316, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. F. M. Giardiello, V. W. Yang, L. M. Hylind et al., “Primary chemoprevention of familial adenomatous polyposis with sulindac,” The New England Journal of Medicine, vol. 346, no. 14, pp. 1054–1059, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. M. H. Wallace and P. M. Lynch, “The current status of chemoprevention in FAP,” Familial Cancer, vol. 5, no. 3, pp. 289–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Steinbach, P. M. Lynch, R. K. S. Phillips et al., “The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis,” The New England Journal of Medicine, vol. 342, no. 26, pp. 1946–1952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Higuchi, T. Iwama, K. Yoshinaga, M. Toyooka, M. M. Taketo, and K. Sugihara, “A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients,” Clinical Cancer Research, vol. 9, no. 13, pp. 4756–4760, 2003. View at Google Scholar · View at Scopus
  40. A. Hallak, L. Alon-Baron, R. Shamir et al., “Rofecoxib reduces polyp recurrence in familial polyposis,” Digestive Diseases and Sciences, vol. 48, no. 10, pp. 1998–2002, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Burn, D. T. Bishop, P. D. Chapman et al., “A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis,” Cancer Prevention Research, vol. 4, no. 5, pp. 655–665, 2011. View at Publisher · View at Google Scholar
  42. Y. H. J. Annie, K. M. Lin, D. M. Ota et al., “Hereditary nonoplyposis colorrectal cancer: preventive management,” Cancer Treatment Reviews, vol. 29, pp. 461–470, 2003. View at Google Scholar
  43. P. Peltomäki and H. Vasen, “Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database,” Disease Markers, vol. 20, no. 4-5, pp. 269–276, 2004. View at Google Scholar · View at Scopus
  44. 2010, http://www.oncoline.nl/.
  45. H. J. Järvinen, M. Aarnio, H. Mustonen et al., “Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer,” Gastroenterology, vol. 118, no. 5, pp. 829–834, 2000. View at Google Scholar · View at Scopus
  46. J. Ruschoff, S. Wallinger, W. Dietmaier et al., “Aspirin supresses the mutador phenotype associated with hereditary non-polyposis colorrectal cancer by genetic selection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, pp. 11301–11306, 1998. View at Google Scholar
  47. A. Goel, D. K. Chang, L. Ricciardiello, C. Gasche, and C. R. Boland, “A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells,” Clinical Cancer Research, vol. 9, no. 1, pp. 383–390, 2003. View at Google Scholar · View at Scopus
  48. J. Burn, D. T. Bishop, J. P. Mecklin et al., “Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome,” The New England Journal of Medicine, vol. 359, no. 24, pp. 2567–2578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Lal, C. Ash, K. Hay et al., “Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor,” Cancer Research, vol. 61, no. 16, pp. 6131–6136, 2001. View at Google Scholar · View at Scopus